In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …

The mRNA vaccine, a groundbreaking advancement in the field of immunology, has
garnered international recognition by being awarded the prestigious Nobel Prize, which has …

Fully targeted mRNA therapeutics necessitate simultaneous organ-specific accumulation
and effective translation. Despite some progress, delivery systems are still unable to fully …

The stemness loss–associated dysregeneration of impaired alveolar type 2 epithelial (AT2)
cells abolishes the reversible therapy of idiopathic pulmonary fibrosis (IPF). We here report …

In designing aerosolized drugs, the challenge lies in achieving optimal penetration and
retention. Existing delivery systems prioritize larger particles for prolonged intrapulmonary …

Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges
such as resistance to shear force damage, mucus penetration, cellular internalization, rapid …

Development of mRNA therapeutics necessitates targeted delivery technology, while the
clinically advanced lipid nanoparticles face difficulty for extrahepatic delivery. Herein, we …

Ionizable lipids are a key component of lipid nanoparticles, the leading nonviral messenger
RNA delivery technology. Here, to advance the identification of ionizable lipids beyond …

Much of current clinical interest has focused on mRNA therapeutics for the treatment of lung-
associated diseases, such as infections, genetic disorders, and cancers. However, the safe …

Messenger RNA (mRNA) therapeutics have been widely employed as strategies for the
treatment and prevention of diseases. Amid the global outbreak of COVID-19, mRNA …